Pharma-Bio Serv, Inc. Logo

Pharma-Bio Serv, Inc.

PBSV

(2.5)
Stock Price

0,53 USD

-5.15% ROA

-5.81% ROE

-16.93x PER

Market Cap.

14.234.022,00 USD

1.7% DER

12.1% Yield

-7.8% NPM

Pharma-Bio Serv, Inc. Stock Analysis

Pharma-Bio Serv, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Pharma-Bio Serv, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE falls within an average range (9.36%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (7.54%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 PBV

The stock's PBV ratio (1.39x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

5 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

6 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

7 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

8 Dividend

The company has consistently provided dividends over the past three years, indicating a reliable source of income for investors.

9 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (5) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

10 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Pharma-Bio Serv, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Pharma-Bio Serv, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Pharma-Bio Serv, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Pharma-Bio Serv, Inc. Revenue
Year Revenue Growth
2005 10.000
2006 14.229.831 99.93%
2007 16.204.851 12.19%
2008 15.196.393 -6.64%
2009 11.479.083 -32.38%
2010 11.346.453 -1.17%
2011 19.933.182 43.08%
2012 29.227.167 31.8%
2013 33.062.010 11.6%
2014 27.555.039 -19.99%
2015 23.384.861 -17.83%
2016 19.536.715 -19.7%
2017 15.579.275 -25.4%
2018 17.797.425 12.46%
2019 19.506.911 8.76%
2020 21.564.360 9.54%
2021 20.115.175 -7.2%
2022 19.398.727 -3.69%
2023 18.308.668 -5.95%
2023 16.976.856 -7.84%
2024 9.672.652 -75.51%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Pharma-Bio Serv, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Pharma-Bio Serv, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 40.000
2006 2.030.737 98.03%
2007 3.176.140 36.06%
2008 3.135.968 -1.28%
2009 2.923.295 -7.28%
2010 2.782.916 -5.04%
2011 3.408.953 18.36%
2012 4.138.111 17.62%
2013 5.761.742 28.18%
2014 6.109.061 5.69%
2015 5.703.111 -7.12%
2016 5.874.991 2.93%
2017 5.036.272 -16.65%
2018 4.598.545 -9.52%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Pharma-Bio Serv, Inc. EBITDA
Year EBITDA Growth
2005 -20.000
2006 4.082.887 100.49%
2007 3.881.680 -5.18%
2008 2.880.977 -34.73%
2009 1.249.748 -130.52%
2010 946.585 -32.03%
2011 3.792.568 75.04%
2012 6.066.424 37.48%
2013 6.426.560 5.6%
2014 3.246.696 -97.94%
2015 2.157.612 -50.48%
2016 332.781 -548.36%
2017 -995.247 133.44%
2018 1.162.863 185.59%
2019 1.795.778 35.24%
2020 2.311.830 22.32%
2021 -3.780.966 161.14%
2022 1.226.052 408.39%
2023 1.887.464 35.04%
2023 1.311.732 -43.89%
2024 -1.349.548 197.2%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Pharma-Bio Serv, Inc. Gross Profit
Year Gross Profit Growth
2005 10.000
2006 6.113.624 99.84%
2007 6.823.935 10.41%
2008 5.789.793 -17.86%
2009 3.838.750 -50.82%
2010 3.392.806 -13.14%
2011 6.860.951 50.55%
2012 9.871.727 30.5%
2013 11.833.456 16.58%
2014 8.973.210 -31.88%
2015 7.484.455 -19.89%
2016 5.783.232 -29.42%
2017 3.611.130 -60.15%
2018 5.686.807 36.5%
2019 6.176.616 7.93%
2020 6.666.722 7.35%
2021 5.359.963 -24.38%
2022 4.881.448 -9.8%
2023 6.200.028 21.27%
2023 5.066.411 -22.38%
2024 2.541.536 -99.34%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Pharma-Bio Serv, Inc. Net Profit
Year Net Profit Growth
2005 -20.000
2006 2.335.340 100.86%
2007 1.901.167 -22.84%
2008 1.487.796 -27.78%
2009 534.757 -178.22%
2010 371.911 -43.79%
2011 3.158.981 88.23%
2012 4.687.006 32.6%
2013 4.906.489 4.47%
2014 2.413.645 -103.28%
2015 1.624.826 -48.55%
2016 -256.575 733.28%
2017 -1.414.909 81.87%
2018 1.279.734 210.56%
2019 2.087.256 38.69%
2020 2.050.922 -1.77%
2021 -2.089.240 198.17%
2022 1.006.684 307.54%
2023 2.104.968 52.18%
2023 1.310.180 -60.66%
2024 -1.236.776 205.94%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Pharma-Bio Serv, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Pharma-Bio Serv, Inc. Free Cashflow
Year Free Cashflow Growth
2005 -30.000
2006 1.452.936 102.06%
2007 5.306.204 72.62%
2008 734.292 -622.63%
2009 1.882.394 60.99%
2010 420.920 -347.21%
2011 2.016.762 79.13%
2012 2.271.704 11.22%
2013 5.407.334 57.99%
2014 3.123.160 -73.14%
2015 30.243 -10226.89%
2016 -1.098.979 102.75%
2017 -1.999.913 45.05%
2018 3.596.675 155.6%
2019 -2.265.118 258.79%
2020 1.469.785 254.11%
2021 793.997 -85.11%
2022 573.188 -38.52%
2023 956.765 40.09%
2023 1.883.709 49.21%
2024 -672.235 380.22%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Pharma-Bio Serv, Inc. Operating Cashflow
Year Operating Cashflow Growth
2005 -30.000
2006 1.557.858 101.93%
2007 5.628.716 72.32%
2008 1.580.106 -256.22%
2009 2.172.531 27.27%
2010 466.349 -365.86%
2011 2.140.273 78.21%
2012 2.459.066 12.96%
2013 5.626.686 56.3%
2014 3.330.667 -68.94%
2015 372.607 -793.88%
2016 709.653 47.49%
2017 -1.548.208 145.84%
2018 3.718.684 141.63%
2019 -2.207.739 268.44%
2020 1.525.442 244.73%
2021 804.842 -89.53%
2022 592.457 -35.85%
2023 956.765 38.08%
2023 1.890.960 49.4%
2024 -670.327 382.1%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Pharma-Bio Serv, Inc. Capital Expenditure
Year Capital Expenditure Growth
2005 0
2006 104.922 100%
2007 322.512 67.47%
2008 845.814 61.87%
2009 290.137 -191.52%
2010 45.429 -538.66%
2011 123.511 63.22%
2012 187.362 34.08%
2013 219.352 14.58%
2014 207.507 -5.71%
2015 342.364 39.39%
2016 1.808.632 81.07%
2017 451.705 -300.4%
2018 122.009 -270.22%
2019 57.379 -112.64%
2020 55.657 -3.09%
2021 10.845 -413.2%
2022 19.269 43.72%
2023 0 0%
2023 7.251 100%
2024 1.908 -280.03%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Pharma-Bio Serv, Inc. Equity
Year Equity Growth
2005 50.000
2006 147.058 66%
2007 2.167.183 93.21%
2008 4.051.780 46.51%
2009 4.662.977 13.11%
2010 5.069.471 8.02%
2011 8.236.325 38.45%
2012 12.875.586 36.03%
2013 18.049.761 28.67%
2014 20.510.761 12%
2015 21.963.104 6.61%
2016 21.810.161 -0.7%
2017 20.747.286 -5.12%
2018 20.263.663 -2.39%
2019 20.607.506 1.67%
2020 22.716.661 9.28%
2021 18.914.131 -20.1%
2022 16.557.570 -14.23%
2023 16.126.785 -2.67%
2023 16.185.481 0.36%
2024 13.686.968 -18.25%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Pharma-Bio Serv, Inc. Assets
Year Assets Growth
2005 50.000
2006 9.140.336 99.45%
2007 9.562.688 4.42%
2008 8.111.953 -17.88%
2009 6.022.281 -34.7%
2010 6.558.024 8.17%
2011 10.852.199 39.57%
2012 15.735.016 31.03%
2013 21.281.936 26.06%
2014 23.211.084 8.31%
2015 24.138.906 3.84%
2016 23.997.701 -0.59%
2017 22.350.001 -7.37%
2018 25.378.312 11.93%
2019 26.633.075 4.71%
2020 29.918.746 10.98%
2021 23.921.201 -25.07%
2022 20.650.846 -15.84%
2023 19.902.061 -3.76%
2023 20.296.599 1.94%
2024 16.318.509 -24.38%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Pharma-Bio Serv, Inc. Liabilities
Year Liabilities Growth
2005 0
2006 8.993.278 100%
2007 7.395.505 -21.6%
2008 4.060.173 -82.15%
2009 1.359.304 -198.69%
2010 1.488.553 8.68%
2011 2.615.874 43.1%
2012 2.859.430 8.52%
2013 3.232.175 11.53%
2014 2.700.323 -19.7%
2015 2.175.802 -24.11%
2016 2.187.540 0.54%
2017 1.602.715 -36.49%
2018 5.114.649 68.66%
2019 6.025.569 15.12%
2020 7.202.085 16.34%
2021 5.007.070 -43.84%
2022 4.093.276 -22.32%
2023 3.775.276 -8.42%
2023 4.111.118 8.17%
2024 2.631.541 -56.22%

Pharma-Bio Serv, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.47
Net Income per Share
-0.04
Price to Earning Ratio
-16.93x
Price To Sales Ratio
1.32x
POCF Ratio
-42.28
PFCF Ratio
-42.13
Price to Book Ratio
1.04
EV to Sales
0.74
EV Over EBITDA
-8.86
EV to Operating CashFlow
-23.6
EV to FreeCashFlow
-23.52
Earnings Yield
-0.06
FreeCashFlow Yield
-0.02
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.7
Graham NetNet
0.53

Income Statement Metrics

Net Income per Share
-0.04
Income Quality
0.4
ROE
-0.06
Return On Assets
-0.05
Return On Capital Employed
-0.08
Net Income per EBT
1.07
EBT Per Ebit
0.67
Ebit per Revenue
-0.11
Effective Tax Rate
-0.07

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.25
Operating Profit Margin
-0.11
Pretax Profit Margin
-0.07
Net Profit Margin
-0.08

Dividends

Dividend Yield
0.12
Dividend Yield %
12.1
Payout Ratio
-4098.16
Dividend Per Share
0.08

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.09
Return on Tangible Assets
-0.05
Days Sales Outstanding
88.05
Days Payables Outstanding
50.41
Days of Inventory on Hand
0
Receivables Turnover
4.15
Payables Turnover
7.24
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,56
Book Value per Share
0,60
Tangible Book Value per Share
0.6
Shareholders Equity per Share
0.6
Interest Debt per Share
0.03
Debt to Equity
0.02
Debt to Assets
0.01
Net Debt to EBITDA
7.01
Current Ratio
8.39
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
14293639
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.5
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Pharma-Bio Serv, Inc. Dividends
Year Dividends Growth
2018 0
2019 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Pharma-Bio Serv, Inc. Profile

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

CEO
Mr. Victor Sanchez
Employee
100
Address
Pharma-Bio Serv Building
Dorado, 00646

Pharma-Bio Serv, Inc. Executives & BODs

Pharma-Bio Serv, Inc. Executives & BODs
# Name Age
1 Mr. Victor Sanchez
Chief Executive Officer, President & President of European Operations
70
2 Mr. Pedro J. Lasanta
Chief Financial Officer, Vice President of Finance & Administration and Secretary
70
3 Ms. Elizabeth Plaza
Founder & Senior Strategic Consultant
70
4 Ms. Miriam Marrero M.B.A.
Human Resources Manager
70

Pharma-Bio Serv, Inc. Competitors